LMAT Strangle Strategy
LMAT (LeMaitre Vascular, Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors.
LMAT (LeMaitre Vascular, Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $2.24B, a trailing P/E of 35.87, a beta of 0.60 versus the broader market, a 52-week range of 78.35-118.01, average daily share volume of 252K, a public-listing history dating back to 2006, approximately 651 full-time employees. These structural characteristics shape how LMAT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.60 indicates LMAT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 35.87 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple. LMAT pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on LMAT?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current LMAT snapshot
As of May 14, 2026, spot at $99.27, ATM IV 30.20%, IV rank 2.32%, expected move 8.66%. The strangle on LMAT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on LMAT specifically: LMAT IV at 30.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a LMAT strangle, with a market-implied 1-standard-deviation move of approximately 8.66% (roughly $8.59 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LMAT expiries trade a higher absolute premium for lower per-day decay. Position sizing on LMAT should anchor to the underlying notional of $99.27 per share and to the trader's directional view on LMAT stock.
LMAT strangle setup
The LMAT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LMAT near $99.27, the first option leg uses a $105.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LMAT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LMAT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $105.00 | $0.86 |
| Buy 1 | Put | $95.00 | $1.45 |
LMAT strangle risk and reward
- Net Premium / Debit
- -$231.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$231.00
- Breakeven(s)
- $92.69, $107.31
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
LMAT strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on LMAT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$9,268.00 |
| $21.96 | -77.9% | +$7,073.20 |
| $43.91 | -55.8% | +$4,878.39 |
| $65.85 | -33.7% | +$2,683.59 |
| $87.80 | -11.6% | +$488.78 |
| $109.75 | +10.6% | +$244.02 |
| $131.70 | +32.7% | +$2,438.82 |
| $153.65 | +54.8% | +$4,633.63 |
| $175.59 | +76.9% | +$6,828.43 |
| $197.54 | +99.0% | +$9,023.24 |
When traders use strangle on LMAT
Strangles on LMAT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LMAT chain.
LMAT thesis for this strangle
The market-implied 1-standard-deviation range for LMAT extends from approximately $90.68 on the downside to $107.86 on the upside. A LMAT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current LMAT IV rank near 2.32% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LMAT at 30.20%. As a Healthcare name, LMAT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LMAT-specific events.
LMAT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LMAT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LMAT alongside the broader basket even when LMAT-specific fundamentals are unchanged. Always rebuild the position from current LMAT chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on LMAT?
- A strangle on LMAT is the strangle strategy applied to LMAT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With LMAT stock trading near $99.27, the strikes shown on this page are snapped to the nearest listed LMAT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LMAT strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the LMAT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 30.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$231.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LMAT strangle?
- The breakeven for the LMAT strangle priced on this page is roughly $92.69 and $107.31 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LMAT market-implied 1-standard-deviation expected move is approximately 8.66%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on LMAT?
- Strangles on LMAT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LMAT chain.
- How does current LMAT implied volatility affect this strangle?
- LMAT ATM IV is at 30.20% with IV rank near 2.32%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.